Conexeu Sciences Inc. – What You Need to Know

Thinking about investing in Conexeu Sciences? First, a reality check: this is not a traditional IPO where the company sells new shares to raise money. This is a "Direct Listing." Here is the plain-English breakdown of what is happening.

1. What is actually happening?

Conexeu Sciences is listing its shares on the Nasdaq under the ticker CNXU. They are not issuing new shares to raise cash. Instead, they are registering existing shares held by early backers so those people can sell their ownership to the public. The company will not receive any money from these sales.

As of March 3, 2026, there are about 20.4 million shares outstanding. Because the company is not raising new capital, it must rely on its existing $4.2 million in cash to fund its research and development.

2. How does the price get set?

In a normal IPO, a bank sets a price before trading starts. Here, there is no set price. On the first day, the Nasdaq will look at buy and sell orders to find a "Current Reference Price." This is the point where the most people are willing to trade.

Because no bank is "stabilizing" the price, the stock could be very jumpy. The opening price may differ significantly from the reference price because no underwriter is there to support the stock during the first days of trading.

3. What does the company do?

Conexeu is a biotech startup focused on "regenerative medicine." Their main project is CXU™, a lab-grown, collagen-based gel. Think of it as a "10-minute tissue" scaffold. You inject it as a liquid, and it turns into a gel to help the body heal wounds or act as an aesthetic filler.

Crucial Note: This product is still in the "preclinical" stage. It has not been approved for sale by the FDA. The company is still testing and has not finalized its regulatory path. They also lack a manufacturing facility and rely on third-party labs, meaning they have no revenue or distribution network.

4. What are the big risks?

• The "All-or-Nothing" Problem: The company has only one product and has never made a dollar in sales. They have lost money every year since 2022, totaling $12.8 million in losses. If CXU™ fails, they have no backup plan.
• Regulatory Minefields: If the product is approved, the company faces strict marketing rules. Promoting it for "off-label" uses could lead to massive fines or a total sales ban.
• Liability & Quality: If the product causes injury or has defects, the company could face expensive lawsuits. They may not have enough insurance to cover these costs.
• Economic Sensitivity: Because their product is often used for aesthetic procedures, a weak economy could cause people to cut back on spending, hurting future sales.
• Competition: They are fighting much larger, well-funded companies. These competitors have more experience, deeper patent portfolios, and established sales teams.
• Volatility: Existing shareholders are free to sell their shares immediately. This could lead to significant downward pressure on the stock price.

How to decide if this is for you

Investing in a pre-revenue biotech company is high-risk. Before you buy, ask yourself:

1. Can I afford to lose this? Given the lack of revenue and the early stage of the product, this is a speculative investment.
2. Have I read the S-1 filing? The company’s official SEC filing contains the full legal details. It’s dry, but it’s the most important document to read before putting your money on the line.
3. Am I comfortable with volatility? Direct listings often experience wild price swings in the first few weeks.

Disclaimer: I am an AI, not a financial advisor. Direct listings can be unpredictable. Always do your own homework, read the official SEC filings, and never invest money you cannot afford to lose.